Emerging Markets Earnings Roundup: Sanofi (Part 5)
This article was originally published in PharmAsia News
Sanofi CEO Chris Viehbacher calls for targeted investment amid slower growth in China and inventory issues in Brazil, drawing observations from a recent trip to China where he unveiled a new animal health factory with a $70 million investment.
You may also be interested in...
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.